Dernières nouvelles pour Cardinal Health (NYSE:CAH) Stock

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and McKesson, the three comprise well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

UBS LUX MSC CANA ETF

Cardinal Health Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is well-poised for growth, given its acquisition-driven strategy, a diversified product portfolio and a robust pharmaceutical segment. However, inflationary pressure remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 11.1% in the year-to-date period against the industry&#39;s 1.7% decline. The S&amp;P 500 Index has gained 20.6% in the same time frame.&nbsp;
CAH, with a market capitalization of $27.09 billion, is a nationwide drug distributor and service provider to pharmacies, healthcare providers and manufacturers. The company has an earnings yield of 6.8% compared with the industry&#39;s 5.3%. It anticipates earnings to improve 9.6% over the next five years.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ce/80495.jpg?v=1119199146" />
Image Source: Zacks Investment Research
<h2>What&#39;s Driving CAH&#39;s Performance?</h2>
Strength in Pharmaceutical Segment:&nbsp;Investors are upbeat about Cardinal Health&#39;s Medical and Pharmaceutical offerings, which provide the company with a competitive edge in the niche space.
The segment&#39;s products and services comprise pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services, which are expected to majorly drive the quarters ahead. For the past few quarters, the segment has been acting as a key catalyst when it comes to driving growth.
In the fourth quarter of fiscal 2024, pharmaceutical revenues amounted to $55.6 billion, up 13% on a year-over-year basis. The performance reflects branded pharmaceutical sales growth from Pharmaceutical Distribution and Specialty Solutions customers.
The company expects revenues from its Pharmaceutical segment to decline 4-6% year over year in fiscal 2025. The anticipated decline reflects a $39 billion revenue headwind due to the OptumRx contract expiration in June 2024. Segmental profit is likely to increase 1-3% from the previous guidance of at least 1%.
Long-term Supply Agreements:&nbsp;Cardinal Health is also pursuing growth via joint ventures and long-term supply agreements with several firms, which have likely kept the investors interested. The company entered into a long-term strategic agreement with Henry Schein. Under this deal, Henry Schein purchased Cardinal Health&#39;s medical supplies for physician practices. The collaboration is expected to drive core sales and prove accretive to CAH&#39;s earnings in the long term.
The signing of a 15-year agreement with Bayer Healthcare for the contract manufacturing of Xofigo is significantly positive. In our opinion, this should help CAH leverage its expertise in the nuclear pharmacy industry to expand access to a therapeutic agent and increase the use of radiopharmaceuticals in the United States and Canada.
Strong Q4 Results:&nbsp;Cardinal Health&#39;s impressive fourth-quarter fiscal 2024 results buoy optimism. The company&#39;s robust top-line results and solid performance in the Pharmaceutical segment were encouraging. Per management, the segmental performance was driven by brand and specialty pharmaceutical sales growth from existing customers.
Gross profit increased 5% year over year, driven by segmental growth.
<h2>Notable Developments</h2>
Last month, CAH announced an agreement to acquire Integrated Oncology Network (&quot;ION&quot;) for $1.115 billion in cash. ION will enhance CAH&#39;s oncology strategy, adding value for providers and patients. The partnership aims to equip community practices with advanced tools and technology, along with expertise from Specialty Networks&#39; PPS Analytics and SoNaR technology, enabling the company to deliver high-quality, patient-centered care close to home, ultimately improving patient outcomes and strengthening CAH&#39;s leadership in healthcare.
Cardinal Health signed a distribution agreement with Australia-based Telix to become the commercial radiopharmaceutical distributor to supply finished unit doses of Telix&#39;s PET agent, Zircaix, for the imaging of kidney cancer in the United States, subject to regulatory approval.
In August, Cardinal Health announced the opening of a new distribution center in Greenville, SC. The distribution center is dedicated to the company&#39;s at-Home Solutions business, which is also expected to add roughly 200 jobs to the region over time. The opening of the new distribution center is likely to provide a boost to CAH&#39;s at-Home Solutions business and generate additional revenues to support the growing market for at-home solutions.
<h2>What&#39;s Weighing on the Stock?</h2>
Cardinal Health faces the risk of losing considerable business in case of loss of a major customer, which, in turn, can severely impair its future revenues. In this regard, post the establishment of a generic sourcing joint venture with CVS Caremark in 2014, Cardinal Health largely depends on the former for more than 20% of its revenues.
Collectively, five of Cardinal Health&#39;s main customers, including CVS, accounted for as much as 40% of its revenues. Meanwhile, the company&#39;s pharmaceutical distribution contracts with OptumRx ended in June 2024. These represented 17% of total revenues in fiscal 2023. The non-renewal of the contracts is likely to adversely impact CAH&#39;s sales in fiscal 2025.
In July, the FDA issued a warning for Cardinal Health&#39;s Presource kit plastic syringe makers, Jiangsu Shenli Medical Production Co. Ltd and Jiangsu China, who have been facing FDA investigation. Recent inspections have unveiled multiple quality system violations, leading to warning letters and import alerts. CAH has recalled the affected products to ensure patient safety and compliance with the FDA regulations.
<div class="chart_embed">
<h3>Cardinal Health, Inc. Price</h3>
<img alt="Cardinal Health, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/e8/1728295731.png" style="height:251px; width:583px" title="" />
Cardinal Health, Inc. price | Cardinal Health, Inc. Quote
</div>
<h2>Estimate Trend</h2>
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $215.84 billion, indicating a 4.9% decline from the previous year&#39;s level.
The Zacks Consensus Estimate for adjusted earnings per share is pinned at $7.61, indicating a 1.1% increase from the year-ago reported numbers. The consensus estimate for adjusted EPS has improved 1 cent over the past 30 days.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;Baxter International&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>), each carrying a Zacks Rank #2 (Buy) at present.
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.58%.
Universal Health Service has gained 17.9% compared with the&nbsp;industry&#39;s&nbsp;19.8% growth in the past six months.
Quest Diagnostics has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics&#39; shares have risen 14.3% in the past six months compared with the&nbsp;industry&#39;s&nbsp;8% growth.
Baxter&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
BAX&#39;s shares have lost 17.9% in the past six months against the&nbsp;industry&#39;s&nbsp;5.8% growth.
<a href="https://www.zacks.com/stock/news/2346905/reasons-to-retain-cardinal-health-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346905">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

News

Guidance

Health Care

Offerings

Contracts

Management

Markets

Analyst Ratings

Trading Ideas

General

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

Biotech

TTOO

T2 Biosystems Enters Multi-Year Exclusive U.S. Agreement With Cardinal Health To Sell FDA-Cleared Direct-From-Blood Diagnostics For Rapid Sepsis Detection, Including T2Dx Instrument, T2Bacteria Panel, And T2Candida Panel

Majorie Taylor Greene disclosed new stock transactions this week, which come as public efforts to ban members of Congress from trading continue to grow over <a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin">potential conflicts of interest.</a>
Here are the latest trades by the Republican House member from Georgia.
 What Happened: Greene has increased her frequency of trading disclosures <a href="https://www.benzinga.com/markets/equities/24/05/38611874/marjorie-taylor-greene-reveals-new-stock-trades-after-2-year-gap-berkshire-hathway-goldman-sachs">in recent months</a> with several large batches of stock purchases announced recently after a two-year hiatus of disclosures.
On Sept. 23, Greene disclosed her latest transactions, as reported by<a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene"> Benzinga's Government Trades page.</a>
Here are the stocks Greene bought, with each one disclosed as a value of $1,000 to $15,000:
<ul>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Berkshire Hathaway B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Southern Copper Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NASDAQ">SCCO</a>)</li>
<li>United Parcel Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
</ul>
Several of these purchases add to recent stakes taken by the representative, including shares of Berkshire Hathaway, Microsoft and CrowdStrike.
The disclosure by Greene did not report any sale transactions, which means the congresswoman continues to hold her Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares <a href="https://www.benzinga.com/general/social-media/24/08/40475137/djt-stock-hits-new-lows-since-trump-media-companys-public-debut-heres-how-much-marjorie-tayl">bought in October 2021.</a>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Greene disclosed buying Digital World Acquisition shares back in October 2021, the SPAC that took Donald Trump's media company public in March 2024.
The transaction was done with shares trading between $67.96 to $118.80. A tweet from UnusualWhales pins the purchase price at $94.20, meaning Greene is down significantly on her $15,000 to $50,000 purchase in the Trump-linked stock. Shares of DJT trade at $13.63 at the time of writing.
Greene buying CrowdStrike shares continues to be an area to watch as <a href="https://www.benzinga.com/general/politics/24/07/39585140/marjorie-taylor-greene-buys-cybersecurity-stock-owned-by-nancy-pelosi-why-trade-could-draw-red-f">Benzinga previously reported</a> the representative sits on the Subcommittee on Cybersecurity, Information Technology and Government Innovation, which operates under the House Committee on Oversight and Accountability.
With the latest stock transactions, Greene has increased her holdings in technology stocks along with placing bets on Warren Buffett to continue powering Berkshire Hathaway along after the stock hit a $1 trillion market capitalization.
Not many can say that their investing portfolios are betting on Donald Trump and Warren Buffett, but Greene can.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Government

Politics

CRWD

GOOG

INTC

LRCX

MSFT

SCCO

Marjorie Taylor Greene Stays Loyal To Trump, Keeps DJT Stock, Buys Into Warren Buffett's Berkshire In Latest Trades

Cardinal Health To Acquire Integrated Oncology Network For $1.115B, Expanding Navista Alliance With Over 100 Providers Across 50 Community-Based Sites In 10 States

Telix Selects Cardinal Health As A Commercial Radiopharmaceutical Distributor To Supply Finished Unit Doses Of Its PET Agent Zircaix For Imaging Of Kidney Cancer In US

Argus Research analyst David Toung maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $115 to $125.

Price Target

Argus Research Maintains Buy on Cardinal Health, Raises Price Target to $125

The City of Baltimore, led by Mayor Brandon M. Scott, reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) to resolve claims against the company for its role in the city&#8217;s opioid epidemic.
Under the agreement, Teva will pay an initial $35 million by the end of 2024, with the remaining amount due by July 1, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40754258/jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-s" rel="noreferrer noopener">JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability</a>.
The <a target="_blank" href="https://mayor.baltimorecity.gov/news/press-releases/2024-09-09-city-baltimore-reaches-80-million-deal-teva-pharmaceuticals-resolve" rel="noreferrer noopener">settlement</a> is part of Baltimore's broader litigation strategy against opioid manufacturers and distributors.
Previous settlements with AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Allergan, CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) have brought in $322.5 million in total recoveries.
The ongoing legal battle will proceed to trial on Sept. 16 against the remaining defendants, who were responsible for more than half of the opioids distributed in Baltimore.
Mayor Scott emphasized the city's decision to opt out of the national Teva settlement, which would have yielded only $11 million over 13 years. Instead, the new agreement brings in more than seven times that amount in under a year.
Baltimore secured more than three times the funds it would have received from global settlements.
Baltimore will dedicate $5 million to education and outreach about the 988 crisis helpline, $3 million to the Penn North Recovery Center and $2 million to BMore Power.
Additional funds will be administered following the framework detailed in the executive order to address the ongoing epidemic.
In July, Teva announced topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent <a href="https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6" target="_blank" rel="noreferrer noopener">patients aged 6-17</a>.
The trial met its primary endpoint with Ajovy achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo.
TEVA Price Action: Teva stock is down 1.43% at $17.55 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40793504/viridian-therapeutics-discloses-exciting-data-from-experimental-thyroid-eye-disease-candidate-say" target="_blank" rel="noreferrer noopener">Viridian Therapeutics Discloses &#8216;Exciting&#8217; Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety</a>.</li>
</ul>
Photo: Ralf Liebhold via Shutterstock

Legal

ABBV

TEVA

Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies

The three largest U.S. drug distributors have reached a settlement of $300 million to resolve claims from health insurers and benefit plans over their alleged role in fueling the opioid epidemic, according to court documents filed on Friday.
The settlement involves McKesson Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), Cencora Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>). The proposed class action settlement, disclosed in a federal court in Cleveland, Ohio, requires a judge&#8217;s approval.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39546645/unitedhealths-optumrx-settles-opioid-prescription-claims-for-20m" rel="noreferrer noopener">UnitedHealth&#8217;s OptumRx Settles Opioid Prescription Claims for $20M</a>.
Reuters highlights that the settlement comes on the heels of a $21 billion agreement by the same companies to settle claims from state and local governments.
Those claims accused the distributors of failing to implement proper controls, which allowed large quantities of addictive painkillers to be diverted into illegal markets.
The new settlement addresses the claims of third-party payers, such as union funds, who bore the financial burden of overprescribed and overmarketed opioid medications and the subsequent treatment of opioid use disorder.
The distributors did not admit any wrongdoing as part of the settlement. The $300 million payment will be divided among the companies, with McKesson paying 38.1%, Cardinal Health and Cencora paying 30.9% and 31%, respectively.
The case is part of a broader wave of litigation against drug manufacturers, distributors, and pharmacies, seeking accountability for a nationwide opioid crisis that has claimed hundreds of thousands of lives over the past two decades.
These lawsuits have collectively resulted in over $50 billion in settlements, primarily with state and local governments.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" target="_blank" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>.</li>
</ul>
Image via Shutterstock

Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers

Cardinal Health Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is a global pharmaceutical and medical products distributor serving over 100,000 hospitals. It&#39;s also the largest distributor of medical supplies and surgical products in the United States. Cardinal Health provides medical supplies and specialty therapeutics to 90% of the hospitals in the United States, as well as 60,000 pharmacies and over 10,000 specialty physician offices.
The rising trend in acute care utilization from emergency rooms, ambulatory and surgical care centers, and inpatient hospital visits has helped drive record results for the company. The stock is also a dividend aristocrat, having raised its dividend for nearly 40 consecutive years.
Cardinal Health operates in the medical sector with major healthcare services companies like McKesson Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>), Stryker Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>), and Cencora Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cor#NYSE">COR</a>).
<h2>Cardinal Health&#39;s Massive Portfolio and Reach </h2>
The company&#39;s professional products range from durable medical equipment to anesthesia supplies, personal protective equipment (PPE), lab supplies, and surgical equipment. It carries over 46,000 home healthcare products to over 3.4 million patients. Its digital ecosystem supports medication adherence to over 23 million patients and over 60 payers. The company offers numerous tailored services, including data and analytics, to improve cost efficiencies, workflows, and waste reduction for ambulatory surgery centers, hospitals, pharmacies, and labs. They even provide customer packaging solutions to pharmaceuticals through its 60,000-square-foot facility with automated and semi-automated equipment accommodating small and large-volume batches and projects in compliance with all FDA standards.
<h2>Cardinal Health: Expanding Its Specialty Business </h2>
Cardinal continues to expand its specialty business, which focuses on distributing and servicing specialty pharmaceuticals, pharmacies, and physician practices. It offers technology platforms that help manage inventory, track patient outcomes, manage reimbursement cycles, and improve efficiency for pharmacies and practices. Specialty therapeutics include a wide array of high-cost, complex medications that often require special storage, handling, and patient support programs. In January 2024, the company agreed to acquire Specialty Networks for $1.2 billion in cash to accelerate growth in its Specialty business. &nbsp;
<img alt="Cardinal Health CAH stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240818185626_chartb-cah.jpg" style="height:750px; width:915px" />
<h2>CAH Stocks Forms a Cup and Handle Breakout Pattern </h2>
The daily candlestick chart for CAH illustrates a cup and handle breakout pattern. The cup lip line at $105.08 was tested on Aug. 8, 2024. The pullback formed the handle staging the rally into its earnings release. CAH gapped to the cup lip line and proceeded to break out higher after testing the support for two days. The daily relative strength index (RSI) has bounced to the 75-band. Pullback support levels are at $105.08, $102.81, $98.79, and $96.05.
<h2>Cardinal Health Beats Top and Bottom Line Estimates </h2>
The fiscal fourth-quarter 2024 earnings report indicated strong top- and bottom-line acceleration. Cardinal Health reported EPS of $1.84, which beat the consensus analyst estimates for $1.74 by 10 cents. Its non-GAAP operating earnings rose 14% to $605 million. Segment profit increases in the Global Medical Products and Distribution and Pharmaceuticals and Specialty Solutions segments primarily drove the growth. Revenues grew 12.1% YoY to $59.87 billion, which also beat the consensus analyst estimate of $58.74 billion.
Fiscal 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectively. Fiscal full-year 2024 revenues rose 11% YoY to $226.8 billion. Full-year non-GAAP diluted EPS rose 29% to $7.53.
<h2>Cardinal Health Raises Its Guidance </h2>
The company issued upside fiscal full-year 2025 non-GAAP EPS of $7.55 to $7.70 versus $7.53 consensus estimates, raising it from previous guidance of $7.50. Full-year revenue is expected to grow 10% to 12% YoY. Its Pharmaceutical and Specialty Solutions segment is expected to see revenues decline 4% to 6% YoY. Its Global Medical Products and Distribution (GMPD) segment is expected to see 3% to 5% revenue growth. Other revenue is expected to grow 10% to 12% YoY.
Cardinal Health CEO Jason Hollar commented, &quot;We delivered robust cash flow generation, continued profit growth in the Pharmaceutical and Specialty Solutions segment and significant improvement driven by our GMPD Improvement Plan. We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance.&quot;
CAH analyst ratings and price targets are at MarketBeat. There are 12 analyst ratings on CAH stock, comprised of seven Buys, two Holds, and one Sell. Consensus analyst price targets point to a 7% upside at $117.45.
The article &quot;<a href="https://www.nasdaq.com/articles/cardinal-health-soars-americas-leading-acute-care-supplier">Cardinal Health Soars as America&#39;s Leading Acute Care Supplier</a>&quot; first appeared on MarketBeat.

Dividends

Cardinal Health Soars as America's Leading Acute Care Supplier

JP Morgan analyst Lisa Gill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $111 to $123.

JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $123

Cardinal Health Announced That Its Plans To Open A New Distribution Center In Walton Hills, Ohio, Supporting Its U.S. Medical Products And Distribution Business

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $115 to $119.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $119

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) has outperformed the market over the past 5 years by 6.06% on an annualized basis producing an average annual return of 19.81%. Currently, Cardinal Health has a market capitalization of $26.35 billion. 
Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,485.05 today based on a price of $108.05 for CAH at the time of writing.
<h3>Cardinal Health's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723820577_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cardinal Health Stock In The Last 5 Years

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $120 to $125.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $125

Wells Fargo analyst Stephen Baxter maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Underweight and raises the price target from $95 to $101.

Wells Fargo Maintains Underweight on Cardinal Health, Raises Price Target to $101

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $114 to $119.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $119

Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b">fourth quarter on Wednesday.</a>
Cardinal Health reported fourth-quarter 2024 adjusted EPS of $1.84, up 29% year over year, beating the consensus of $1.73.
Sales increased 12% to $59.87 billion, beating the consensus of $58.64 billion. The pharmaceutical segment revenue increased 12% to $55.6 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
Cardinal Health raised its fiscal year 2025 adjusted EPS guidance to $7.55-$7.70 from the preliminary outlook of at least $7.50 versus the consensus of $7.53.
The company updated its Pharmaceutical and Specialty Solutions segment profit growth outlook to 1%-3% growth from at least 1%. For the Global Medical Products and Distribution segment, the company expects revenue growth of 3%-5%. Overall revenue is expected to grow between 10%-12%.
"We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance," said Jason Hollar, CEO of Cardinal Health.
Cardinal Health shares closed at $106.36 on Wednesday.
These analysts made changes to their price targets on Cardinal Health following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> maintained Cardinal Health with an Outperform and raised the price target from $130 to $137.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ece538c4a1e100001de8a1a/elizabeth-anderson">Evercore ISI Group analyst Elizabeth Anderson</a> maintained Cardinal Health with an In-Line and boosted the price target from $105 to $115.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40393013/pfizer-conagra-brands-and-2-other-stocks-insiders-are-selling">Pfizer, Conagra Brands And 2 Other Stocks Insiders Are Selling</a></li>
</ul>
Considering buying CAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png" alt="" class="wp-image-496733" style="width:414px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings

Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a In-Line and raises the price target from $105 to $115.

Evercore ISI Group Maintains In-Line on Cardinal Health, Raises Price Target to $115

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our a<a href="https://www.benzinga.com/analyst-stock-ratings">nalyst ratings page.</a>
<ul>
<li>Rosenblatt raised the price target for Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) from $65 to $69. Rosenblatt analyst Mike Genovese maintained a Buy rating. Lumentum shares fell 1.5% to close at $45.53 on Wednesday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $250 to $252. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Progressive shares gained 5.4% to close at $234.34 on Wednesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Century Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) price target from $11 to $9. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Century Therapeutics shares fell 5.5% to close at $1.56 on Wednesday. <a href="https://www.benzinga.com/quote/IPSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from $200 to $130. Wells Fargo analyst Michael Turrin downgraded the stock from Overweight to Equal-Weight. Snowflake shares gained 0.2% to close at $127.30 on Wednesday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) price target from $56 to $58. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Cisco shares gained 0.2% to close at $45.44 on Wednesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs increased The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $199 to $204. Goldman Sachs analyst Alex Scott maintained a Buy rating. Allstate shares gained 5.2% to close at $180.95 on Wednesday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS increased the price target for Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from $76 to $90. UBS analyst Danielle Antalffy upgraded the stock from Sell to Neutral. Medtronic shares fell 0.6% to close at $81.74 on Wednesday.<a href="https://www.benzinga.com/quote/MDT/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Citigroup cut Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) price target from $170 to $155. Citigroup analyst Asiya Merchant maintained a Buy rating. Dell shares gained 3% to close at $102.95 on Wednesday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) price target from $130 to $137. Baird analyst Eric Coldwell maintained an Outperform rating. Cardinal Health shares rose 3.7% to close at $106.36 on Wednesday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) price target from $21 to $24. Deutsche Bank analyst Brian Bedell upgraded the stock from Hold to Buy. Robinhood shares gained 1.3% to close at $18.65 on Wednesday. S<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">ee how other analysts view this stock.</a></li>
</ul>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>
Considering buying Robinhood stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-1024x571.png" alt="" class="wp-image-496664" style="width:511px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115.png 1240w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Pre-Market Outlook

CSCO

DELL

HOOD

IPSC

LITE

SNOW

Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday

Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Outperform and raises the price target from $130 to $137.

Baird Maintains Outperform on Cardinal Health, Raises Price Target to $137

Deutsche Bank analyst George Hill maintained a Hold rating on Cardinal Health (CAH – Research Report) today and set a price target of $119.00. The ...

Deutsche Bank  Sticks to Its Hold Rating for Cardinal Health (CAH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Thermo Fisher (TMO – Research Report), Cardinal Heal...

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Cardinal Health (CAH) and Sanofi (OtherSNYNF)

Pioneer Balanced ESG Fund Q2 2024 Performance And Market Commentary

Pioneer Global Sustainable Equity Fund Q2 2024 Performance And Market Commentary

Dividend Champion, Contender, And Challenger Highlights: Week Of September 29

Investing in value stocks is appealing now due to their strong long-term performance and affordability, as interest rates decline and inflation stabilizes, providing a lower-risk opportunity before Wall Street takes notice. Hence, it may be wise to add fundamentally strong value stocks like Stellantis (STLA), Centene (CNC), and Cardinal Health (CAH) to one's portfolio now. Read on… Value stocks are increasingly attractive now due to their historically strong long-term performance, especially as interest rates decline. With inflation stabilizing and many stocks facing potential overvaluation, value stocks present a lower-risk opportunity for investors seeking reliable returns.
Therefore, investors could consider buying fundamentally strong value stocks such as Stellantis N.V. (<a href="https://stocknews.com/stock/STLA/">STLA</a>), Centene Corporation (<a href="https://stocknews.com/stock/CNC/">CNC</a>), and Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>) for their discounted valuations and solid fundamentals, before Wall Street catches on.
U.S. inflation is decelerating, contributing to economic stability. Gross domestic product (GDP) grew at an annualized <a href="https://www.reuters.com/markets/us/us-second-quarter-economic-growth-unrevised-gdi-revised-sharply-higher-2024-09-26/">3.0% in Q2 2024</a>, while gross domestic income (GDI) surged to a revised 3.4%. These positive trends reflect a balanced economic environment with improved corporate profits, reduced inflationary pressures, and stronger consumer spending.
Despite ongoing uncertainties, the recent <a href="https://www.forbes.com/advisor/investing/fed-rate-cut-impact-prices/">50 basis point rate cut</a> by the Fed has the potential to foster greater economic stability, increase profits through reduced borrowing costs, and enhance investor confidence. This environment makes undervalued stocks particularly appealing, as they stand to gain from improved earnings potential and a more positive market sentiment.
Considering these trends, let's assess the fundamentals of the abovementioned value stocks.
Stellantis N.V. (<a href="https://stocknews.com/stock/STLA/">STLA</a>)
Headquartered in Hoofddorp, the Netherlands, STLA designs, manufactures, distributes, and sells automobiles and light commercial vehicles, engines, transmission systems, metallurgical products, mobility services, and production systems worldwide.
On September 30, 2024, STLA announced that Leapmotor International has opened orders for the T03 and C10 electric vehicles in Europe through STLA's brand dealers. This joint venture aims to expand global sales of affordable, high-tech electric vehicles, with deliveries expected later this year.
On September 17, 2024, STLA inaugurated its global commercial vehicles hub at Mirafiori Automotive Park 2030 in Turin, Italy, to streamline cross-brand functions and strengthen leadership in the commercial vehicle market. STLA Pro One aims to enhance efficiency and global operations, with commercial vehicles accounting for one-third of the company's total net revenue.
In terms of forward non-GAAP <a href="https://www.investopedia.com/terms/p/price-earningsratio.asp">P/E</a>, STLA's 3.48x is 80% lower than the 17.39x industry average. Its 1.57x forward EV/EBITDA is 84.8% lower than the 10.36x industry average. Likewise, its 2.28x forward EV/EBIT is 85.2% lower than the 15.44x industry average.
STLA's net revenues for the first half ended June 30, 2024, stood at €85.02 billion ($94.91 billion). Its net profit attributable to the owners of the parent was €5.62 billion ($6.27 billion), and its adjusted operating income came in at €8.46 billion ($9.44 billion). Furthermore, the company's adjusted EPS was €2.36.
Street expects STLA's EPS and revenue for fiscal 2025 to increase 12.6% and 4.9% year-over-year to $5.20 and $196.98 billion, respectively. Over the past month, the stock has declined 4.3% to close the last trading session at $16.06.
STLA's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect robust prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
STLA is ranked #14 out of 54 stocks in the <a href="https://stocknews.com/category/auto-vehicle-makers/">Auto &amp; Vehicle Manufacturers</a> industry. It has an A grade for Value and a B for Stability. To see STLA's Growth, Momentum, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/STLA/">click here</a>.
Centene Corporation (<a href="https://stocknews.com/stock/CNC/">CNC</a>)
CNC operates as a healthcare enterprise that provides programs and services to underinsured and uninsured families, commercial organizations, and military families. The company operates through segments including Medicaid, Medicare, Commercial, and Other.
On September 23, 2024, CNC's subsidiary, Health Net, was selected to provide managed dental care services for Medi-Cal beneficiaries in Los Angeles and Sacramento counties under a new 54-month contract starting July 1, 2025. Health Net will serve nearly 385,000 members in these counties.
On September 4, 2024, CNC's subsidiary, Iowa Total Care, was awarded a four-year statewide Medicaid contract by the Iowa Department of Health and Human Services to continue providing Medicaid managed care services under the Iowa Health Link program. The contract begins July 1, 2025, with a potential two-year extension.
In terms of forward non-GAAP PEG, CNC's 1.38x is 30.1% lower than the 1.97x industry average. Likewise, its 10.92x forward non-GAAP P/E is 49.9% lower than the 21.78x industry average. Also, its 0.25x forward EV/Sales is 93.2% lower than the 3.69x industry average.
In the fiscal second quarter that ended June 30, 2024, CNC's total revenues rose 5.9% year-over-year to $39.84 billion. Likewise, its earnings from operations rose 5% from the year-ago value to $1.23 billion. The company's adjusted net earnings and adjusted EPS increased 11.1% and 15.2% over the prior-year quarter to $1.28 billion and $2.42, respectively.
For the quarter ending September 30, 2024, CNC's revenue is expected to increase marginally year-over-year to $38.08 billion. Its EPS for the quarter ending December 31, 2024, is expected to rise 45.8% year-over-year to $0.66. CNC surpassed the Street EPS estimates in each of the trailing four quarters. Over the past three months, the stock has gained 10.7% to close the last trading session at $74.58.
CNC's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Value and a B for Growth and Quality. Within the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry, it is ranked #2 out of 10 stocks. To access the additional POWR Ratings of CNC for Momentum, Stability, and Sentiment, <a href="https://stocknews.com/stock/CNC/">click here</a>.
Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>)
CAH operates as a healthcare services and products company internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and home-based patients. The company operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution.
On September 20, 2024, CAH announced its agreement to acquire Integrated Oncology Network (ION) for $1.12 billion in cash. The acquisition will expand CAH's Navista oncology practice alliance, adding over 100 providers across more than 50 community-based sites in 10 states.
On August 21, 2024, CAH announced plans to open a new 249,000-square-foot distribution center in Walton Hills, Ohio, by spring 2025. The facility will feature advanced technology and automation to enhance medical product distribution efficiency and customer service.
In terms of forward Price/Sales, CAH's 0.12x is 96.8% lower than the 3.78x industry average. Its 10.53x forward EV/EBIT is 37.6% lower than the 16.89x industry average. Likewise, its 14.40x forward non-GAAP P/E is 33.9% lower than the 21.78x industry average.
CAH's revenue for the fourth quarter, which ended on June 30, 2024, increased 12.1% year-over-year to $59.87 billion. Its non-GAAP gross margin rose 5.5% over the prior-year quarter to $1.88 billion. For the same quarter, the company's non-GAAP net earnings and non-GAAP EPS were $450 million and $1.84, respectively, up by 22.6% and 28.7% compared to the prior-year quarter.
Analysts expect CAH's EPS for the quarter ending March 31, 2025, to increase 5% year-over-year to $2.18. Its revenue for fiscal 2026 is expected to grow 8.2% year-over-year to $234.25 billion. It surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past year, CAH's stock has gained 24.7% to close the last trading session at $109.79.
CAH's POWR Ratings reflect this positive outlook. CAH has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Growth and Value and a B for Stability. Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> sector, it is ranked #3 out of 60 stocks. To access additional grades for CAH's Momentum, Sentiment, and Quality, <a href="https://stocknews.com/stock/CAH/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
STLA shares were trading at $13.96 per share on Monday afternoon, down $2.10 (-13.08%). Year-to-date, STLA has declined -40.14%, versus a 21.21% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/stla-cnc-cah-3-value-stocks-to-buy-now-before-wall-street-catches/>3 Value Stocks to Buy Now Before Wall Street Catches On</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Value Stocks to Buy Now Before Wall Street Catches On

Shelton Equity Income Strategy Q2 2024 Commentary

If I Had To Invest $150,000 Right Now, Here's What I Would Buy

AAPL

ACWI

AMAT

AMZN

AVGO

BABA

BABAF

BPOP

CADE

CFFI

CHCO

CHRW

CMCSA

CTBI

CTSH

CUBE

EBAY

ERIE

EXPE

FFIN

FISI

FMAO

FOXA

FTNT

FULT

FUNC

GAIN

GILD

GOOGL

HAGHY

HBNC

HLNE

HNSDF

HWBK

INDB

INGR

LULU

MBIN

MORN

MSCI

NTAP

NVDA

PRYMF

PRYMY

PSTG

QCOM

QQQM

RGLD

RYDAF

SCHD

SCHG

SCVL

SFBS

SFNC

SHEL

SNYNF

SPLG

SPTN

SSNC

STLA

STLD

SWBI

SYBT

THFF

TRGP

TRMB

TSLA

UBSI

ULTA

UMBF

UTMD

VICI

VRSN

WASH

WSBC

Press Releases

Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2024 on August 14

Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health expands medical product distribution footprint in Northeast Ohio

Cardinal Health celebrates Greenville, South Carolina, distribution center opening

Children's Hospital Association and Cardinal Health commemorate World Suicide Prevention Day with continued focus on youth mental health

Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®

Cardinal Health to acquire Integrated Oncology Network, a physician-led independent community oncology network

Cardinal Health to Announce First-Quarter Results for Fiscal Year 2025 on November 1

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

Comments

Cardinal Health

Actualités

Dernières nouvelles pour Cardinal Health (NYSE:CAH) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL